Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Lipopolysaccharide transport protein A (LptA) is a periplasmic protein featuring a novel fold made up of 16 consecutive antiparallel beta-strands arranged in a twisted beta-jellyroll configuration. LptA participates as part of a bridge in the Lpt machinery, facilitating unidirectional movement of LPS molecules from the inner membrane to the outer membrane in Gram-negative bacteria. It assembles in a head-to-tail fashion to form fibers capable of shuttling LPS and interacts with other Lpt proteins (LptC and LptD) to ensure cell envelope integrity. Loss or mutation of LptA impairs LPS transport, sensitizing bacteria to environmental threats and antibiotics. LptA, together with other Lpt proteins (LptB-G), is indispensable for the survival of Gram-negative bacteria, making the Lpt transporter a highly attractive target for novel antibiotic development, especially amid rising multidrug resistance.
Drugs may inhibit LptA directly or trap LPS during transport, preventing proper cell envelope formation and increasing bacterial permeability
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lipopolysaccharide transport protein A (LptA).